About Retinitis Pigmentosa
Retinitis pigmentosa (RP) is a group of inherited retinal dystrophies characterized by progressive degeneration of photoreceptor cells, particularly affecting rod cells initially with secondary cone involvement developing later in disease course. The disease follows various inheritance patterns including autosomal recessive, autosomal dominant, and X-linked, with over 100 different genes now implicated in RP inheritance.
Patients typically first notice night blindness and difficulty adapting to darkness, as rod photoreceptors (responsible for dim light vision) are preferentially affected early. This is followed by progressive loss of peripheral vision creating the characteristic tunnel vision phenotype as disease advances centrally over years to decades. On ophthalmologic examination, characteristic bone-spicule-shaped pigmentary changes appear in the retina, along with optic disc pallor and vascular attenuation as hallmark findings.
Electroretinography confirms progressive photoreceptor dysfunction with reduced or extinguished responses. With progression, most patients develop significant central vision loss by late adulthood, though progression rates vary considerably. Genetic heterogeneity means different mutations cause varying clinical presentations, progression rates, and extraocular manifestations. Some patients retain useful vision into late life while others progress more rapidly.
Common Symptoms of Retinitis Pigmentosa
Recognizing the signs of Retinitis Pigmentosa early can lead to faster diagnosis and better outcomes. Symptoms may vary in severity from person to person. If you or a loved one are experiencing any of the following, consider speaking with a specialist.
- Night blindness and difficulty seeing in dim light
- Progressive peripheral vision loss
- Tunnel vision in later stages
- Difficulty adapting to light changes
- Floaters and dark spots in vision
- Gradual central vision loss
Who Retinitis Pigmentosa Affects
Retinitis pigmentosa typically manifests in childhood or early adulthood, though age of onset varies considerably from infancy to later adult years depending on genetic subtype.
The condition affects males and females equally in autosomal recessive and dominant forms, though X-linked forms predominantly affect males while females serve as carriers. All ethnic backgrounds are affected, with different genetic subtypes varying in frequency across populations. Some subtypes show higher prevalence in specific geographic regions or populations. Age of symptom onset, progression rate, and clinical severity vary depending on the specific causative gene mutation.
Find Your Next Step
Answer a few questions and we'll point you to the right tools and information for where you are right now.
FDA-Approved Treatments for Retinitis Pigmentosa
There is currently 1 FDA-approved medication for Retinitis Pigmentosa. These therapies represent the current standard of care and may be used alongside or compared against investigational treatments in active clinical trials.
Source: openFDA drug labeling data. This list may not include all treatments. Always consult your doctor.
Help Paying for Retinitis Pigmentosa Treatment
Charity funds and drugmaker programs for Retinitis Pigmentosa, checked at the source. Pick your insurance to see what fits.
No charity fund for this condition is open right now. Funds reopen when they receive new donations; the foundations let you sign up to be told when one opens.
Side Effect Explorer
Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.
Loading side effect data...
Genetic Testing
Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.
Finding labs...
Trusted Retinitis Pigmentosa Resources
Reputable organizations and medical references for learning more about Retinitis Pigmentosa, including disease registries, foundation resources, and clinical guidelines.